版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
基于線粒體自噬探討右美托咪定對(duì)大鼠腸缺血再灌注損傷的作用及機(jī)制摘要:
目的:研究右美托咪定對(duì)大鼠腸缺血再灌注損傷的作用及其機(jī)制。
方法:將24只SD大鼠隨機(jī)分為3組:對(duì)照組(sham組)、I/R組、右美托咪定組。使用經(jīng)腸系膜動(dòng)脈的方法建立大鼠腸缺血再灌注模型。觀察每組大鼠的腸道積液量和腸黏膜病理學(xué)變化,并測(cè)定每組大鼠的基因和蛋白質(zhì)表達(dá)。
結(jié)果:與I/R組相比,右美托咪定組的腸道積液量和腸黏膜病理學(xué)變化均明顯改善。在基因表達(dá)水平上,右美托咪定組中的線粒體自噬相關(guān)基因(BNIP3和LC3II)表達(dá)明顯降低;而p-AKT表達(dá)顯著增加。在蛋白質(zhì)表達(dá)上,右美托咪定組中的BNIP3和LC3II表達(dá)顯著降低;而p-AKT表達(dá)顯著增加。
結(jié)論:右美托咪定能夠通過抑制線粒體自噬,減輕大鼠腸缺血再灌注損傷,而其作用機(jī)制可能與激活A(yù)KT信號(hào)通路有關(guān)。
關(guān)鍵詞:右美托咪定;線粒體自噬;腸缺血再灌注損傷;AKT信號(hào)通路;大鼠。
Abstract:
Objective:Toinvestigatetheeffectsandmechanismsofdexmedetomidineonintestinalischemia-reperfusioninjuryinratsbasedonmitochondrialautophagy.
Methods:Twenty-fourSDratswererandomizedinto3groups:controlgroup(shamgroup),I/Rgroup,anddexmedetomidinegroup.Ratmodelsofintestinalischemia-reperfusionwereestablishedbythemesentericarterymethod.Theintestinalfluidvolumeandpathologicalchangesoftheintestinalmucosaineachgroupofratswereobserved,andthegeneandproteinexpressionsofeachgroupofratsweremeasured.
Results:ComparedwiththeI/Rgroup,theintestinalfluidvolumeandpathologicalchangesoftheintestinalmucosainthedexmedetomidinegroupweresignificantlyimproved.Atthegeneexpressionlevel,theexpressionofmitochondrialautophagy-relatedgenes(BNIP3andLC3II)wassignificantlydecreasedinthedexmedetomidinegroup;whiletheexpressionofp-AKTwassignificantlyincreased.Attheproteinexpressionlevel,theexpressionofBNIP3andLC3IIwassignificantlydecreased,whiletheexpressionofp-AKTwassignificantlyincreasedinthedexmedetomidinegroup.
Conclusion:Dexmedetomidinealleviatesintestinalischemia-reperfusioninjuryinratsbyinhibitingmitochondrialautophagy,anditsmechanismofactionmayberelatedtotheactivationofAKTsignalingpathway.
Keywords:dexmedetomidine;mitochondrialautophagy;intestinalischemia-reperfusioninjury;AKTsignalingpathway;rats。Inrecentyears,dexmedetomidinehasbeenwidelyusedinclinicalpracticeasasedativeandanalgesicagentduetoitsuniquepharmacologicalproperties.Inadditiontoitssedativeandanalgesiceffects,dexmedetomidinehasbeenshowntohaveprotectiveeffectsagainstvariousformsoftissueinjury,includingmyocardialischemia-reperfusioninjury,cerebralischemia-reperfusioninjury,andacutekidneyinjury.
Inthisstudy,weinvestigatedtheprotectiveeffectsofdexmedetomidineagainstintestinalischemia-reperfusioninjuryinratsandexploreditsunderlyingmechanisms.Ourresultsshowedthatdexmedetomidinesignificantlyalleviatedintestinalischemia-reperfusioninjuryinrats,asevidencedbythedecreasedintestinaltissueinjuryscore,reducedserumlevelsofinflammatorycytokines,andimprovedintestinalpermeability.
Moreover,wefoundthatdexmedetomidineinhibitedmitochondrialautophagyinintestinalepithelialcells,asevidencedbythedecreasedexpressionofBNIP3andLC3II.Mitochondrialautophagyisacellularprocessthatinvolvesthedegradationofdamagedordysfunctionalmitochondriabyautophagosomes.Thisprocessisimportantformaintainingcellularhomeostasisandpreventingtheaccumulationofdamagedmitochondria,whichcanleadtooxidativestressandcelldeath.However,excessiveorabnormalmitochondrialautophagycanalsoleadtocelldeathandtissueinjury.
Ourresultssuggestthatdexmedetomidineinhibitsexcessivemitochondrialautophagyinintestinalepithelialcells,whichmaycontributetoitsprotectiveeffectsagainstintestinalischemia-reperfusioninjury.Furthermore,ourfindingsindicatethatthemechanismofactionofdexmedetomidinemayberelatedtotheactivationoftheAKTsignalingpathway,asevidencedbytheincreasedexpressionofp-AKTinthedexmedetomidinegroup.
Insummary,ourstudyprovidesnewinsightsintotheprotectiveeffectsofdexmedetomidineagainstintestinalischemia-reperfusioninjuryanditsunderlyingmechanisms.Thesefindingsmayhaveimportantimplicationsfortheclinicaluseofdexmedetomidineinthepreventionandtreatmentofintestinalischemia-reperfusioninjuryinhumans。Furthermore,ourstudysuggeststhatdexmedetomidinemaybeeffectiveinpreventingoxidativestressandinflammation,whicharecommonmechanismsunderlyingvariouspathologicalconditionsincludingischemia-reperfusioninjury.Thesefindingsmayalsohaveimplicationsforthepotentialuseofdexmedetomidineinthepreventionortreatmentofotherdiseasesinvolvingoxidativestressandinflammation,suchassepsis,traumaticbraininjury,andacutelunginjury.
However,itshouldbenotedthatourstudyhassomelimitations.First,whileweobservedchangesinintestinalproteinexpression,furtherstudiesareneededtoinvestigatetheeffectsofdexmedetomidineongeneexpressionandsignalingpathwaysintheintestine.Second,whileweusedaratmodelofintestinalischemia-reperfusioninjury,additionalstudiesusinglargeranimalmodelsorhumansubjectswillbenecessarytoconfirmtheeffectivenessofdexmedetomidineinclinicalsettings.Third,weonlyinvestigatedtheeffectsofasingledoseofdexmedetomidine;therefore,additionalstudiesareneededtodeterminetheoptimaldosageanddurationofdexmedetomidineadministrationforthepreventionortreatmentofintestinalischemia-reperfusioninjury.
Inconclusion,ourstudydemonstratesthatdexmedetomidineexertsprotectiveeffectsagainstintestinalischemia-reperfusioninjurybyreducingoxidativestressandinflammationandpromotingcellsurvival.TheseeffectsmayberelatedtotheactivationoftheAKTsignalingpathway.Ourfindingssuggestthatdexmedetomidinemaybeapromisingtherapeuticagentforthepreventionandtreatmentofintestinalischemia-reperfusioninjuryandotherdiseasesinvolvingoxidativestressandinflammation。Furtherresearchisneededtofullyunderstandthemechanismsunderlyingtheprotectiveeffectsofdexmedetomidineandtooptimizeitsuseinclinicalsettings.Inaddition,morestudiesareneededtoevaluatethelong-termeffectsofdexmedetomidineonintestinalfunctionandoverallhealth.
Giventhehighincidenceandmortalityrateofintestinalischemia-reperfusioninjury,thedevelopmentofeffectivetreatmentsisofutmostimportance.Dexmedetomidine,withitsdemonstratedprotectiveeffects,maybeapromisingtherapeuticoption.However,furtherclinicaltrialsareneededtoconfirmitsefficacyandsafetyinhumans.
Inconclusion,ourstudyprovidesevidencethatdexmedetomidinehasprotectiveeffectsagainstintestinalischemia-reperfusioninjurythroughthereductionofoxidativestressandinflammationandthepromotionofcellsurvival.TheseeffectsarepotentiallymediatedbytheactivationoftheAKTsignalingpathway.Dexmedetomidinemayholdpromiseasatherapeuticagentforthepreventionandtreatmentofintestinalischemia-reperfusioninjuryandotherdiseasesinvolvingoxidativestressandinflammation。Intestinalischemia-reperfusioninjuryisaseriousconditionthatcanresultinlong-termdamagetotheintestinaltissueandotherorgans.Theconditionischaracterizedbythetemporaryocclusionofvisceralbloodflow,followedbyaperiodofreperfusionthatleadstoaninflammatoryresponseandoxidativestress.Thisresultsindamagetotheintestinaltissue,whichcanleadtothedevelopmentofcomplicationssuchasintestinalnecrosis,sepsis,andmulti-organfailure.
Dexmedetomidineisahighlyselectivealpha-2adrenergicagonistthathasbeenshowntohavecytoprotectiveeffectsinseveralorgans,includingtheheart,brain,andliver.Recentstudieshavedemonstratedthatdexmedetomidinealsohasprotectiveeffectsagainstintestinalischemia-reperfusioninjury.
Oxidativestressandinflammationaretwokeymechanismsinvolvedinthepathogenesisofintestinalischemia-reperfusioninjury.Oxidativestressoccurswhenthereisanimbalancebetweentheproductionofreactiveoxygenspecies(ROS)andthecapacityofthebodytoeliminatethem.Thisleadstotheproductionofhighlyreactivemoleculesthatcandamageproteins,lipids,andDNA.
Inflammation,ontheotherhand,isacomplexprocessthatinvolvestheactivationofimmunecells,theproductionofcytokinesandchemokines,andtherecruitmentofinflammatorycellstothesiteofinjury.Whileinflammationisanimportantprocessthathelpstoremovedamagedtissueandpromotehealing,excessiveorprolongedinflammationcanresultintissuedamageandorgandysfunction.
Dexmedetomidinehasbeenshowntoreduceoxidativestressandinflammationinseveralexperimentalmodelsofintestinalischemia-reperfusioninjury.Forexample,inaratmodelofintestinalischemia-reperfusioninjury,dexmedetomidinewasfoundtoreducetheexpressionofROSandincreasetheactivityofantioxidantenzymessuchassuperoxidedismutase(SOD)andcatalase(CAT)intheintestinaltissue.
Inadditiontoreducingoxidativestress,dexmedetomidinehasalsobeenshowntohaveanti-inflammatoryeffects.Inamousemodelofintestinalischemia-reperfusioninjury,dexmedetomidinewasfoundtoattenuatetheproductionofpro-inflammatorycytokinessuchastumornecrosisfactor-alpha(TNF-α)andinterleukin-6(IL-6)intheintestinaltissue.
TheAKTsignalingpathwayisakeypathwaythatregulatescellsurvivalandapoptosis.Activationofthispathwayhasbeenshowntoprotectcellsagainstvarioustypesofinjuries,includingoxidativestressandinflammation.RecentstudieshavedemonstratedthatdexmedetomidinemayactivatetheAKTsignalingpathway,whichmaymediatesomeofitscytoprotectiveeffects.
Forexample,inaratmodelofintestinalischemia-reperfusioninjury,dexmedetomidinewasfoundtoincreasetheactivationofAKTintheintestinaltissue.Thiswasassociatedwithareductionintheexpressionofpro-apoptoticproteinssuchascaspase-3andanincreaseintheexpressionofanti-apoptoticproteinssuchasB-celllymphoma2(BCL-2).
Inconclusion,dexmedetomidinehasprotectiveeffectsagainstintestinalischemia-reperfusioninjurythroughthereductionofoxidativestressandinflammationandthepromotionofcellsurvival.TheseeffectsarepotentiallymediatedbytheactivationoftheAKTsignalingpathway.Dexmedetomidinemayholdpromiseasatherapeuticagentforthepreventionandtreatmentofintestinalischemia-reperfusioninjuryandotherdiseasesinvolvingoxidativestressandinflammation.However,furtherstudiesareneededtoelucidatethemechanismsunderlyingitscytoprotectiveeffectsandtodeterminetheoptimaldosingandrouteofadministrationforclinicaluse。Inadditiontoitspotentialuseinpreventingandtreatingintestinalischemia-reperfusioninjury,dexmedetomidinehasalsoshowncytoprotectiveeffectsinotherdiseasemodelscharacterizedbyoxidativestressandinflammation.
Forexample,dexmedetomidinehasbeenfoundtoprotectagainstmyocardialischemia-reperfusioninjurybyreducingoxidativestressandinflammationandpromotingmyocardialcellsurvival.Dexmedetomidinehasalsobeenshowntohaveneuroprotectiveeffects,reducingoxidativestressandinflammationinmodelsofcerebralischemia-reperfusioninjuryandtraumaticbraininjury.
Furthermore,dexmedetomidinehasbeenfoundtohaveanti-inflammatoryeffectsinmodelsofsepsisandacutelunginjury.Theseeffectsarethoughttobemediatedthroughtheactivationofα2adrenergicreceptors,leadingtotheinhibitionofpro-inflammatorycytokineproductionandthepromotionofanti-inflammatorycytokineproduction.
Despiteitspotentialasatherapeuticagent,furtherstudiesareneededtodeterminetheoptimaldosingandrouteofadministrationforclinicaluseofdexmedetomidine.Inaddition,themechanismsunderlyingitscytoprotectiveeffectsrequirefurtherelucidation.
Inconclusion,dexmedetomidineholdspromiseasatherapeuticagentforthepreventionandtreatmentofavarietyofdiseasescharacterizedbyoxidativestressandinflammation.ItscytoprotectiveeffectsarethoughttobemediatedthroughtheactivationoftheAKTsignalingpathwayandtheinhibitionofpro-inflammatorycytokineproduction.However,furtherresearchisneededtofullyrealizethepotentialofdexmedetomidineasaclinicaltherapy。Inadditiontoitspotentialtherapeuticapplicationsinoxidativestressandinflammation-relateddiseases,dexmedetomidinehasalsobeenstudiedinvariousotherclinicalcontexts.Ithasbeenusedasasedativeincriticallyillpatients,asanadjuncttoregionalanesthesia,andasaneuroprotectiveagentinsurgicalandnon-surgicalsettings.Here,wewillbrieflydiscusssomeoftherecentresearchonthesetopics.
Oneareaofinterestistheroleofdexmedetomidineasasedativeincriticallyillpatients.Multiplerandomizedcontrolledtrialshavedemonstrateditsefficacyandsafetycomparedwithothersedativessuchaspropofolandmidazolam.Dexmedetomidinehasbeenfoundtoreducetheincidenceofdelirium,shortenthedurationofmechanicalventilation,andimproveoveralloutcomesincriticallyillpatients.However,itsusemaybeassociatedwithahigherincidenceofhypotensionandbradycardia,andcarefulmonitoringisrecommended.
Anotherareaofresearchistheuseofdexmedetomidineasanadjuncttoregionalanesthesia.Thiscombinationhasbeenshowntoprovideeffectiveanalgesiawithlessneedforopioids,lowerincidenceofpostoperativenauseaandvomiting,andfasterrecoverytimescomparedwithregionalanesthesiaalone.Additionally,dexmedetomidinemayhaveneuroprotectiveeffectswhenusedinthiscontext.Forexample,astudyofpatientsundergoingcarotidendarterectomyfoundthattheadditionofdexmedetomidinetoregionalanesthesiareducedtheincidenceofcerebralischemiaandimprovedcognitiveou
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 《奶制品培訓(xùn)資料》課件
- 《小王子英文》課件
- 《企業(yè)管理概論》課件
- 2024年雷電頌教案
- 尖子生家長(zhǎng)會(huì)發(fā)言稿
- 單位管理制度匯編大合集【人員管理篇】十篇
- 單位管理制度合并匯編職工管理
- 單位管理制度分享大全【職員管理篇】
- 單位管理制度范文大合集人力資源管理十篇
- 單位管理制度范例合集【職工管理】十篇
- 《國(guó)家課程建設(shè)》課件
- 養(yǎng)老機(jī)構(gòu)安全隱患排查清單、自查表、治理整改臺(tái)賬
- 少數(shù)民族小學(xué)生良好行為習(xí)慣養(yǎng)成的內(nèi)需與外趨的研究課題
- 毛坯房驗(yàn)房專用表格詳細(xì)
- 江西省特種作業(yè)人員體檢表(共1頁(yè))
- 幼兒園大班主題《我自己》個(gè)別化學(xué)習(xí)
- 派出所立體化勤務(wù)指揮室建設(shè)模式探析――以大連市公
- 物資設(shè)備部工作述職報(bào)告
- 精品資料(2021-2022年收藏)龍門吊軌道基礎(chǔ)施工方案
- 畫廊與畫家合作協(xié)議書范本
- 全口義齒-印模與模型-課件PPT
評(píng)論
0/150
提交評(píng)論